Clinical trials: Irritation
Irritable Bowel Syndrome (IBS)
Personalized Probiotic Treatments for Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is characterized by stomach pain and altered bowel habits. It affects about 5 million people in Canada. Doctors don't fully understand what causes IBS, so treatments often don't work well.
- Trial name
- NCT07872514
- Testing
- Probiotic containing B longum, Probiotic Lactobacillus
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- McMaster University
Inflammatory Bowel Diseases, Irritable Bowel Syndrome
Assessment of Anorectal Function in Patients With Inflammatory Bowel Disease
Active inflammatory bowel disease (IBD) causes disabling symptoms such as diarrhea, involuntary loss of bowel control, abdominal pain and urges to pass stool.
- Trial name
- NCT05185609
- Testing
- Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS, Exposure 2: Changes in anorectal motor function or compliance.
- Where
- Sweden
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Region Örebro County
Irritable Bowel Syndrome
Probiotics and Irritable Bowel Syndrome
This clinical trial was conducted on 90 IBS patients, who fulfill ROME IV criteria and the IBS diagnostic questionnaire (Arabic version licensed by Rome Foundation) in Egyptair hospital outpatient clinic, Cairo, Egypt between May…
- Trial name
- NCT04572932
- Testing
- lactobacillus delbruekii
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Ocular Dryness, Ocular Irritation
Dry Eye and Irritation Comparison of Latanoprost With the Preservative Versus Travoprost Without Preservative
Although Benzalkonium chloride (BAC) has been used as a preservative for many years, many studies have demonstrated that prolonged use of topical ocular medications preserved with BAC may exacerbate sequelae associated with…
- Conditions
- Ocular Dryness, Ocular Irritation, Open-Angle Glaucoma, Ocular Hypertension
- Trial name
- NCT00803387
- Testing
- Travaprost without BAC (Travatan Z)
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- United States Air Force
Abdominal Pain
Objective Integrated Multimodal Electrophysiological Index for the Quantification of Visceral Pain
The objectives of the study are to 1) Conduct telemetric biosignals (EDA, ECG, and EMG) recording in healthy controls and IBS participants experiencing cutaneous and visceral pain; and 2) Validate the OIME index as a biomarker…
- Trial name
- OIME (NCT06381921)
- Testing
- IBS-PPSM intervention
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Connecticut
Irritable Bowel Syndrome
Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome
The purpose of this study is to determine if two different probiotic strains, Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175, are effective in helping subjects manage the symptoms of IBS
- Trial name
- 14PIHL (NCT02213172)
- Testing
- Bifidobacterium longum R0175, Lactobacillus paracasei HA-196
- Where
- Canada
- Volunteers
- 285 people
- Sponsor
- KGK Science Inc.
IBS - Irritable Bowel Syndrome
Efficacy of Virtual Reality (VR) for Irritable Bowel Syndrome
In this study, the investigators conduct a remote, eight-week, two-arm, randomized controlled trial that assesses the benefits, primarily measured through the irritable bowel syndrome (IBS)-targeted HRQOL (health-related quality…
- Trial name
- NCT06257472
- Testing
- Virtual Reality Headset
- Where
- 2 sites in United States
- Sponsor
- Anthony Lembo
Irritable Bowel Syndrome
The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study
The purpose of this study is to evaluate the effects of long acting mesalamine (Lialda) in patients with Post-Infective Irritable Bowel Syndrome (PI-IBS).
- Trial name
- Mesalamine (NCT01412372)
- Testing
- Mesalamine
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Utah
Breast Feeding, Constipation
A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically
The purpose of this study is to determine the amount of linaclotide and its active metabolite (MM-419447) excreted in breast milk after multiple, once daily doses of linaclotide (72 μg, 145 μg, or 290 μg) in lactating women…
- Conditions
- Breast Feeding, Constipation, Irritable Bowel Syndrome
- Trial name
- LIN-PK-01 (NCT02220348)
- Testing
- linaclotide
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Forest Laboratories
Irritable Bowel Syndrome
Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel Syndrome With Impaired Intestinal Permeability
Irritable bowel syndrome (IBS) affects approximately 5% of the general population and remains a daily problem in the practice of clinicians with inconsistent effectiveness of treatments while patients' expectations are high.
- Trial name
- MISSISIIPI (NCT06291038)
- Testing
- • Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks, • Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.
- Where
- 4 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Rouen
Gastrointestinal Diseases, Chronic Pain
Web-Based Survey of Pain, Stress and Complementary and Alternative Medicine
The investigators are inviting people with fibromyalgia, IBS, interstitial cystitis, chronic pain, and other chronic and recurring conditions to sign up and participate in a year-long Internet-based survey to study the…
- Conditions
- Gastrointestinal Diseases, Chronic Pain, Stress, Anxiety
- Trial name
- PROCAIM (NCT00740233)
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Non-erosive Gastroesophageal Reflux Disease, Functional Dyspepsia
Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial
Background: Functional gastrointestinal disorder (FGID) is the most common gastrointestinal disease in daily clinical practice. The disease is symptomatic but has no identifiable cause by standard diagnostic tests such as…
- Conditions
- Non-erosive Gastroesophageal Reflux Disease, Functional Dyspepsia, Irritable Bowel Syndrome
- Trial name
- FGISP-RCT (NCT01047800)
- Testing
- Counseling
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Effect of a Probiotic Formula on Reducing SIBO in IBS Patients
This randomized study evaluates the effectiveness of the a probiotic formula, compared with the antibiotic rifaximin, in the treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Irritable Bowel Syndrome (IBS) patients.
- Trial name
- NCT04316806
- Testing
- Probiotic, Rifaximin
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- AB Biotics, SA
Irritable Bowel Syndrome
Association Between High Faecal Calprotectin, Increased Intestinal Permeability and Visceral Hypersensitivity in IBS-D Patients
Visceral hypersensitivity, low grade inflammation and increased intestinal permeability are three main pathophysiological mechanisms involved in irritable bowel syndrome. The connexion between these abnormalities is not known.
- Trial name
- SIIMPA (NCT02550704)
- Testing
- Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability
- Where
- France
- Volunteers
- 34 people
- Sponsor
- University Hospital, Rouen
Irritable Bowel Syndrome
Caecal pH as a Biomarker for Irritable Bowel Syndrome
Irritable bowel syndrome is common. Currently, it is a diagnosis of exclusion. There is increasing evidence of the importance of the microbiota in the pathophysiology of this disorder.
- Trial name
- NCT02360384
- Testing
- Linaclotide, FODMAP diet
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Wingate Institute of Neurogastroenterology
Colonic Diseases, Functional
Dietary Interventions in Irritable Bowel Syndrome: Soluble, Insoluble or no Fibre?
The purpose of this study is to assess the role of dietary fibre in Irritable Bowel Syndrome (IBS) treatment, in particular the role of increasing the content of soluble or insoluble fibres in the daily diet.
- Trial name
- NCT00189033
- Testing
- psyllium fibre (dietary supplement), wheat bran (dietary supplement)
- Where
- 2 sites in Netherlands
- Volunteers
- 285 people
- Sponsor
- UMC Utrecht
Irritable Bowel Syndrome
Well-being in IBS: Strengths and Happiness (WISH) 2.0
The purpose of this study is to examine the feasibility, acceptability, preliminary effects, and candidate gut-brain mechanisms of an optimized positive psychology (PP) intervention for patients with irritable bowel syndrome…
- Trial name
- NCT06866106
- Testing
- Positive Psychology (PP) Intervention, Educational Intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Disruptive Behavior, Aggression
Cognitive-Behavioral Therapy for Disruptive Behavior in Children and Adolescents
This is a randomized controlled study of cognitive-behavioral therapy (CBT) for disruptive behavior such as irritability, anger and aggression in children and adolescents.
- Conditions
- Disruptive Behavior, Aggression, Anger, Irritability
- Trial name
- RDoC-CBT (NCT01965184)
- Testing
- Cognitive-Behavioral Therapy for Anger and Aggression, Supportive Psychotherapy (SPT)
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Yale University
Irritable Bowel Syndrome (IBS)
Investigating the Gut Microbiome and Symptomology in IBS
This intervention study explores whether a routine physical activity intervention can help manage or relieve symptoms of Irritable Bowel Syndrome (IBS) in adults who have been clinically diagnosed with IBS.
- Trial name
- MICROFIT (NCT06708533)
- Testing
- Physical Activity
- Volunteers
- 40 people
- Sponsor
- Nottingham Trent University
Diarrhea- Irritable Bowel Syndrome
The Effect of Neu-P11 on Symptoms in Patients With D-IBS
Placebo controlled double-blind study with 40 patients who have an diarrhea-predominant IBS, 20 get Neu-P11, 20 get a placebo. Neu-P11 is a, Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B…
- Trial name
- Neu-P11 (NCT01558284)
- Testing
- Neu-P11
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Ludwig-Maximilians - University of Munich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.